Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo

SHUFANG XIE1,2*, WEIMIN FAN2,3*, CHEN YANG2,4, WEN LE5, HONGYING PAN6, XIANGMIN TONG2,7, YI WU8 and SHIBING WANG2,7

1The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310000; 2Molecular Diagnosis Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014; 3Department of Center for Reproductive Medicine, Taihe Hospital, Affiliated to Hubei University of Medicine, Shiyan, Hubei 442000; 4Department of Clinical Medicine, Qingdao University, Qingdao, Shandong 266071; 5Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003; 6Department of Infectious Diseases, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014; 7The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital; 8Department of Hematology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

Received June 11, 2020; Accepted December 4, 2020

DOI: 10.3892/or.2021.7942

Correspondence to: Dr Yi Wu, Department of Hematology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 158 Shangtang Road, Hangzhou, Zhejiang 310014, P.R. China
E-mail: wuyi10000@126.com

Dr Shibing Wang, Molecular Diagnosis Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 158 Shangtang Road, Hangzhou, Zhejiang 310014, P.R. China
E-mail: wangshibing@hmc.edu.cn

*Contributed equally

Abstract. Non-Hodgkin lymphoma (NHL) is a form of lymphoid malignancy, with diffuse large B cell lymphoma (DLBCL) being the most common NHL isoform. Approximately half of patients with DLBCL are successfully cured via first‑line Rituximab, Cyclophosphamide, Epirubicin, Vindesine, Prednisolone (R‑CHOP) treatment. However, 30‑40% of patients with DLBCL ultimately suffer from treatment-refractory or relapsed disease. These patients often suffer from high mortality rates owing to a lack of suitable therapeutic options, and all patients are at a high risk of serious treatment-associated dose-dependent toxicity. As such, it is essential to develop novel treatments for NHL that are less toxic and more efficacious. Oncolytic Vaccinia virus (OVV) has shown promise as a means of treating numerous types of cancer. Gene therapy strategies further enhance OVV-based therapy by improving tumor cell recognition and immune evasion. Beclin1 is an autophagy‑associated gene that, when upregulated, induces excess autophagy and cell death. The present study aimed to develop an OVV‑Beclin1 therapy capable of inducing autophagic tumor cell death. OVV‑Beclin1 was able to efficiently kill NHL cells and to increase the sensitivity of these cells to R‑CHOP, thereby decreasing the dose-dependent toxic side effects associated with this chemotherapeutic regimen. The combination of OVV‑Beclin1 and R‑CHOP also significantly improved tumor growth inhibition and survival in a BALB/c murine model system owing to the synergistic induction of autophagic cell death. Together, these findings suggest that OVV‑Beclin1 infection can induce significant autophagic cell death in NHL, highlighting this as a novel means of inducing tumor cell death via a mechanism that is distinct from apoptosis and necrosis.

Introduction

Non-Hodgkin lymphoma (NHL) is a form of lymphoid malignancy that can manifest in lymph nodes and other lymphatic organs (1). NHL is one of the 10 most common forms of cancer globally, with ~500,000 newly diagnosed cases annually. There are ≥40 major subtypes of NHL with various genetic, clinical, and morphological features. Diffuse large B cell lymphoma (DLBCL) is the most common form of NHL, accounting for 30‑40% of new cases. Rituximab, Cyclophosphamide, Epirubicin, Vindesine, Prednisolone (R‑CHOP) is the first-line standard of care treatment for these patients and can achieve a 60% overall survival (OS) rate (2); however, up to 40% of...
patients suffer from treatment-refractory or relapsed disease with associated high mortality rate (3,4). Chemotherapeutic drugs can cause extensive DNA damage within both tumor and healthy cells (5), such that even patients that survive chemotherapy suffer significant systemic toxicity and renal failure in a dose-dependent manner (6).

A number of alternative therapeutic regimens have been developed to overcome the aforementioned limitations and toxicity of standard R-CHOP therapy, including oncolytic Vaccinia virus (OVV) and gene therapies (7-9). OVV approaches allow for direct tumor cell targeting, whereas gene therapy allows precise genetic manipulation in target cells. A previous OVV and gene therapy-based study have focused on the induction of apoptosis within tumor cells (10). However, apoptosis is a complex process and certain tumor cells are resistant to apoptotic cell death (11), limiting the potential utility of correliative therapeutic strategies. In addition to apoptotic death, cells can also undergo autophagic death. Under normal physiological conditions, autophagy is a process whereby cells respond to stress and maintain homeostasis and proper protein folding by degrading intracellular protein aggregates and organelles (12,13). Beclin1 is a key regulator of autophagy that facilitates co-localization of other autophagic proteins to promote autophagosome formation and maturation in mammalian cells (14). Beclin1 has been found to function as a tumor suppressor gene in breast, ovarian and other types of cancer (15,16). The specific degree of autophagy is important: Moderate levels of autophagy improve cell survival under stressful conditions, whereas excessive autophagy triggers cell death (17-19). Chemotherapeutic drugs cause extensive DNA damage, but tumor cells can develop resistance to such damage by modulating intracellular DNA repair capability (20). Increasing autophagic activity within tumor cells can lead to the degradation of these organelles and proteins associated with DNA repair, potentially increasing their susceptibility to chemotherapy (21-23).

The present study investigated a potential therapeutic strategy aimed at increasing intratumoral Beclin1 expression levels as a means of inducing autophagic cell death, based on previous research (24-26). OVV-Beclin1 was developed as a therapeutic approach to induce NHL cell death and increasing sensitivity to chemotherapeutic treatment. Levels of the autophagosome marker LC3B in NHL cells were assessed via western blotting following OVV-Beclin1 treatment to confirm efficacy. Tumor inhibitory effects of OVV-Beclin1 treatment were confirmed via MTT and colony formation assays, as well as an in vivo murine model system.

Materials and methods

Human samples, cell lines and reagents. Pathological biopsy and paracancerous tissue samples were obtained from 10 patients with NHL that underwent fine-needle aspiration and biopsy at Zhejiang Provincial People's Hospital (Hangzhou, China) from January 2015 to December 2016. All samples were collected in a manner consistent with Chinese law and the study was approved by the Ethics Committee of Zhejiang People's Hospital (approval no. 2019KY232), and all patients provided written informed consent. As DLBCL tumors are invasive, paracancerous tissue samples were selected from the same region as the primary tumor (distance, >5 cm).

OCI-LY3 and Pfeiffer cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and were grown in RPMI-1640 (HyClone; GE Healthcare Life Sciences) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin. Additionally, 293 cells were obtained from the Institute of Clinical Medicine of Zhejiang Provincial People's Hospital and maintained in DMEM containing 10% FBS, 2 mM L-glutamine (both Gibco; Thermo Fisher Scientific, Inc.) and penicillin/streptomycin. Cells were cultured in a humidified 5% CO2 incubator at 37°C.

Anti-Beclin1 (1:1,000; clone 2A4; cat. no. 4122), anti-LC3A/B (1:1,000; clone D3U4C; cat. no. 13118) and anti-P62 (1:1,000; clone Ser403; cat. no. 39786) were obtained from Cell Signaling Technology, Inc., while anti-caspase-3 (1:500; cat. no. ab13847) was from BioWest; Anti-PARP (1:500; cat. no. 100984-T46) was purchased from Abcam; Epirubicin was from Shenzhen Main Luck Pharmaceuticals, Inc., Vindesine was from Yangtze River Pharmaceutical Group Co., Ltd. and Prednisolone was from Pfizer, Inc.

Immunohistochemistry (IHC) and hematoxylin and eosin (H&E) staining. Samples from patients with DLCBL (n=10; median age: 70; range: 55-81 years) were fixed with 10% formalin at room temperature for >24 h, embedded in paraffin and cut into 4-μm sections. Sections were deparaffinized with xylene, rehydrated using an ethanol gradient (100, 95, 90, 80 and 70%) and antigen recovery was performed using sodium citrate buffer at 121°C and 80 kPa. Endogenous peroxidase activity was quenched using a 3% H2O2 solution to treat samples for 15 min at room temperature. Following three washes in PBS, sections were stained with anti-Beclin1 (1:200) overnight at 4°C. Sections were then washed and stained with appropriate horseradish peroxidase (HRP)-labeled secondary antibodies for 30 min at room temperature, as previously described (16). Sections were again washed with PBS, stained for 15 min with 3’3’-diaminobenzidine at room temperature, and then counterstained with hematoxylin at room temperature for 4 min. Sections were examined via light microscopy (Shanghai Laika Microscope Co., Ltd.; magnification, x400) and were then assessed with Image-Pro Plus software (Image-Pro Express 6.0; Media Cybernetics, Inc.).

OVV-Beclin1 preparation and characterization. A homologous recombination approach was used for OVV and OVV-Beclin1 preparation, as previously described (27-29). The
complete Beclin1 gene sequence was amplified via PCR from the plasmid (cat. no. HG11162-ACG; Sino Biological, Inc.) with the following primers: Forward: 5'-CCCGGATCCACATGGAGGTTAGACGTTCAAGACGTCCACAAC-3' and reverse, 5'-ACGCGTCGACTTACATTGGTTATCCAAAATGGTGAAGG-3'. The PCR conditions were as follows: Initial denaturation, 95°C, 3 min; denaturation, 95°C, 45 sec; annealing, 55°C, 45 sec; elongation, 72°C, 90 sec (30 cycles) and final extension, 72°C, 5 min. This sequence was then inserted into the pCB plasmid via molecular cloning. The sequence was verified, after which pCB or pCB-Beclin1 underwent homologous recombination with wild-type Vaccinia virus in 293A cells, as previously described (28). When significant infection and associated suppression effects were evident, as previously described (30), these 293 cell cultures were expanded and used to harvest prepared virus particles. Viral particles were then purified by repeated freezing and thawing (freezing temperature, -80°C; thawing temperature, 37°C; 3 cycles for 15 min each). Cell samples followed by ultracentrifugation (750 x g; 4°C; 10 min). The median tissue culture infective dose for these OVV particles was then measured.

Acridine orange staining. Acridine orange was used to stain acidic autophagosomes within NHL cells, as previously described (31,32). Briefly, these cells were treated with PBS, OVV, or OVV-Beclin1 (MOI, 50) for 48 h at 37°C and were then stained with acridine orange for 15 min. Cell fluorescence was then assessed via fluorescence microscopy (magnification, x400; excitation, 560 nm; emission, 645 nm) as previously described (32).

Western blotting. Proteins in OCI-LY3 cells and murine tumor tissue were extracted using RIPA (Beyotime Institute of Biotechnology) buffer containing protease inhibitors, after which a BCA assay kit was used to measure protein levels in these samples. Equal amounts of protein (10 μg) were then separated via SDS-PAGE (10-15%), and samples were transferred to PVDF membranes and probed at 4°C overnight with appropriate primary antibodies. Membranes were blocked with ~5% milk in TBST (0.05% Tween-20) for 1 h at room temperature. Blots were then probed at room temperature for 1 h with secondary HRP-conjugated antibody (1:4,000; HuaAn Biotechnology Co., Ltd) for 1 h. Protein bands were detected via enhanced chemiluminescence detection system (Thermo Fisher Scientific, Inc.) and quantification was performed using ImageJ software (1.48v; National Institutes of Health).

MTT assay. OCI-LY3 cells were seeded in 96-well plates (2x10^4 cells per well) and cultured at 37°C for 12 h. PBS was used as the control. In order to assess cell death, cells were treated with the apoptosis inhibitor z-VAD and/or the autophagy inhibitor baflomycin A1 (BAF1; both 10 μM; both Selleck Chemicals). Following incubation at 37°C for 72 h, 20 μl MTT reagent (Promega Corporation) was added to each well and cultured for 4 h at 37°C with 5% CO₂. Finally, the absorbance was detected at a wavelength of 490 nm using a Microplate Reader Model 550 nm. (Bio-Rad Laboratories, Inc.).

Colonies formation assay and growth curves. OCI-LY3 cells were infected with OVV-green fluorescent protein (GFP) or OVV-Beclin1(MOI=50 and 100) in a 6-well plate for 12 h at 37°C, and the cell density is 10^6/well. After which they were washed twice in PBS, seeded in 24-well plates (density, 10^3/ml) in a solution containing 2.7% methylcellulose and 200 μl FBS and cultured for 10 days at 37°C, after which colonies (>50 cells) were counted via light microscopic examination. (magnification, x10).

**Murine xenograft experiments.** Female nude mice (n=25; age, 5 weeks; weight, 23.5 g) were raised in the Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, China) received a subcutaneous right flank injection of 1x10^6 OCI-LY3 cells. Mice received standard diet and water ad libitum and were housed under specific pathogen-free conditions. Beginning on day 9 after injection of OCV-LY3 cells, when tumors were ~100 mm³, tumor volume was measured and animals were randomized into five treatment groups (n=5/group): PBS (100 μl), OVV (10⁸ PFU/animal; intratumoral injection), OVV-Beclin1 (10⁸ PFU/animal; intratumoral injection), R-CHOP (Rituximab, 375.0; Cyclophosphamide, 750.0; Epirubicin, 50.0; Vindesine, 1.4; Prednisolone, 15.0 mg/m²; caudal vein injection) and R-CHOP + OVV-Beclin1 (administered with the same dosing strategies as in the R-CHOP-alone and OVV-Beclin1-alone groups). For mice administered R-CHOP therapy, Rituximab (2.74 mg) was administered on day 1 (the day on which tumor volume reached ~100 mm³) CHO (5.40, 0.36 and 0.01 mg, respectively) was administered on day 2 (the day after R-CHOP therapy) and Prednisolone (0.11 mg) administered on days 2-5. For animals treated with both OVV-Beclin1 and R-CHOP, OVV-Beclin1 was administered prior to R-CHOP as aforementioned. Following treatment, tumor volume was monitored every other day using calipers and calculated as follows: 0.5 x length x width². After 30 days, mice were sacrificed via cervical dislocation. Tumors were harvested, fixed with 10% formalin, paraffin-embedded and used for downstream analysis as aforementioned. The Animal Center of Zhejiang Chinese Medical University (Hangzhou, China) approved the present study, which was performed in accordance with appropriate guidelines and regulations (33).

**Statistical analysis.** SPSS 17.0 software (SPSS, Inc.) was used for statistical analysis. Data are presented as the mean ± SD of three independent repeats. Continuous data were compared via unpaired two-tailed Student's t-tests or two-way ANOVA followed by Tukey's multiple comparisons post hoc test as appropriate. The Kaplan-Meier approach and log-rank test were used to compare survival outcomes and Prism (version. no. 8.0.2; GraphPad Software, Inc.) was used to construct figures. P<0.05 was considered to indicate a statistically significant difference.

**Results.**

**Clinical characteristics of patients with NHL.** The clinical characteristics of patients with NHL are shown in Table I. Beclin1 expression levels in these NHL tumor tissue samples were assessed via IHC, revealing notably decreased Beclin1 levels in tumor cells compared with normal control cells (Fig. I). Beclin1 staining (brown) was very weak in NHL...
tissue, suggesting that Beclin1 downregulation may be associated with NHL progression.

**Assessment of OVV-Beclin1 infectivity in NHL cells.** OVV-Beclin1 was generated via homologous recombination (Fig. 2A). OVV infectivity was assessed using an OVV-GFP construct, which was used to infect the OCI-LY3 and Pfeiffer NHL cell lines. These cells were readily infected by this virus, with a dose-dependent increase in the frequency of GFP-positive cells from 30 to 60% on day 2 post-infection as viral MOI rose from 10 to 50 (Fig. 2B and C). Autophagic changes in cells were assessed. Western blotting demonstrated that the OVV-Beclin1 treatment was associated with notably increased Beclin1 and LC3B levels and decreased those of P62 (Fig. 2D), suggesting that cytotoxicity was associated with increased induction of autophagy. In order to confirm that the OVV-Beclin1 virus was capable of inducing autophagy in NHL cells, Beclin1 levels in these cells were measured via western blotting; OVV-Beclin1 led to a dose-dependent increase in levels of this protein in NHL cell preparations (MOI=10-50). By contrast, mock-infected cells exhibited relatively low levels of Beclin1 protein. Other autophagy-associated protein levels in these cells were assessed, including levels of LC3B, which forms during autophagy and is associated with the membrane of autophagosomes, and SQSTM1(P62), which is a ubiquitin-binding protein that exhibits decreased expression as autophagy progresses (34). Measurements of these proteins in OVV-Beclin1-infected NHL cells (Fig. 2E) further confirmed that the virus was able to effectively induce autophagy within NHL cells following infection. This indicates that these cells

---

**Table I. Clinical characteristics of patients with non-Hodgkin lymphoma.** Beclin1 levels were analyzed in 10 randomly selected patients with DLBCL, revealing no association between Beclin1 levels and patient sex, age or immunophenotype.

| Patient | Sex/age, years | Classification | Immunohistochemical staining results |
|---------|----------------|----------------|-------------------------------------|
| 1       | Female/81      | GCB            | CD3(-), CD20(+), CD45(-), CD10(+), PAX5(+) |
| 2       | Male/55        | Non-GCB        | PAX5(++), CD45(-), CD10(-), BCL-6(+), MUMI(-) |
| 3       | Male/62        | Non-GCB        | CD3(-), CD20(+), CD45(-), CD10(-), BCL-6(-), MUMI(-) |
| 4       | Male/64        | GCB            | CD3(-), CD20(+), CD45(-), CD10(-), BCL-6(-), MUMI(-) |
| 5       | Male/77        | Non-GCB        | CD3(-), CD20(+), CD45(-), CD10(-), BCL-6(+), MUMI(+) |
| 6       | Female/67      | Non-GCB        | CD3(-), CD20(+), CD45(-), CD10(-), BCL-6(+), MUMI(+) |
| 7       | Female/76      | Non-GCB        | CD3(-), CD20(+), CD45(-), CD10(-), BCL-6(+), MUMI(+) |
| 8       | Male/55        | Non-GCB        | CD3(-), CD20(+), CD45(-), CD10(-), BCL-6(+), MUMI(+) |
| 9       | Female/51      | Non-GCB        | CD3(-), CD20(+), CD45(-), CD10(-), BCL-6(-), MUMI(+) |
| 10      | Female/63      | Non-GCB        | CD3(-), CD20(+), CD45(-), CD10(-), BCL-6(-), MUMI(+) |

Pan B cell type: CD3(-), CD20(+), CD45(-), PAX5(+). GCB: CD10(+) or BCL-6(+), MUMI(-). Non-GCB: CD10(-), MUMI(+) or BCL-6(-), MUMI(-). DLBCL, diffuse large B cell lymphoma; GCB, germinal center type DLBCL.

Figure 1. Beclin1 expression levels are decreased in patients with DLBCL. DLBCL (affected lymph nodes) and adjacent normal tissue were stained for Beclin1. Cytoplasmic Beclin1 levels (brown) were lower in DLBCL compared with paired normal tissue. Representative images are shown. Scale bar, 50 µm. DLBCL, diffuse large B cell lymphoma.
were highly sensitive to OVV-Beclin1 infection. Infection with a 50 or 100 MOI dose of OVV-Beclin1 notably inhibited cell viability, as demonstrated by colony formation assay. In order to ensure the best infection effect, virus titer was tested during the experiment. The results showed that after 48 h infection, the virus titer was significantly higher than at 24 h (Fig. 2F and G).

**OVV-Beclin1 induces autophagic cell death in NHL.** Having demonstrated that the OVV-Beclin1 was capable of efficiently infecting NHL cells and inducing autophagy, it was next determined whether this virus drove autophagic cell death. Levels of apoptosis-associated proteins were measured via western blotting; expression levels were not significantly altered following OVV-Beclin1 infection (Fig. 3A). In further support of this result, treatment of NHL cells with the apoptosis inhibitor z-VAD did not prevent OVV-Beclin1-induced cell death (Fig. 3B), indicating that death occurred in a caspase-independent manner. During autophagy, acidic autophagosomes form and interact with microtubule-associated protein LC3B (35). Autophagic vesicles were therefore detected via staining with acid-sensitive acridine orange (Fig. 3C). These autophagosomes contained protein, debris and organelles such as mitochondria, confirming successful OVV-Beclin1-mediated autophagic induction. Treating these cells with the autophagy inhibitor BAF1 prevented OVV-Beclin1-induced cell death. Together, these findings confirmed the ability of OVV-Beclin1 to induce autophagy in NHL cells, with BAF1 inhibiting this process (Fig. 3D).

**OVV-Beclin1 and R-CHOP exhibit synergistic efficacy in vivo.** The aforementioned results were next assessed in vivo to determine whether OVV-Beclin1 in combination with R-CHOP may be a viable treatment for NHL. A murine NHL xenograft model was established by subcutaneously implanting BALB/c nude mice with OCI-LY3 cells. After tumors had grown to ~100 mm³, animals were randomized into 5 treatment groups (PBS, OVV, OVV-Beclin1, R-CHOP and OVV-Beclin1 + R-CHOP). OVV-Beclin1 was administered intratumorally every third day over the course of three treatment cycles and PBS and R-CHOP were injected via the caudal vein. Tumor volume in these mice was then monitored ≥3 times per week, and animals exhibiting signs of...
terminal disease or excessive tumor growth were euthanized (Fig. 4A). Mice treated with PBS or OVV exhibited larger tumors than mice treated with OVV-Beclin1, R-CHOP or OVV-Beclin1 + R-CHOP, suggesting that OVV-mediated Beclin1 expression significantly suppressed tumor growth and final tumor weight (Fig. 4B-C). Compared with OVV-Beclin1- or R-CHOP-alone, combined OVV-Beclin1 + R-CHOP treatment significantly prolonged survival (Fig. 4D).

These results suggested that OVV-Beclin1 treatment was able to confer significant survival benefits. In order to confirm that Beclin1 levels were altered, Beclin1 levels in murine tumor tissue were assessed via IHC. This analysis revealed that tumors from the PBS, OVV and R-CHOP groups exhibited less pronounced Beclin1 staining compared with the OVV-Beclin1 and OVV-Beclin1 + R-CHOP groups. This was confirmed this by calculating the frequency of Beclin1-positive cells per unit area relative to that in the PBS control group. H&E staining was performed to observe the changes of cells in tumor tissue samples: Necrosis was highest in the OVV-Beclin1 + R-CHOP, indicating that the combination of OVV-Beclin1 and OVV-Beclin1 and R-chop exerted a cytotoxic effect (Fig. 4E and F).

**Discussion**

A previous study (36) has demonstrated the value of OVV approaches to cancer treatment, as these viruses exhibit superior tumor selectivity and decreased toxicity compared with traditional therapies (37-39). OVV is harmless in normal cells but can effectively kill target tumor cells (40). The OVV genome is large, stable and contains a number of non-essential genes, making it an ideal vector for the delivery of recombinant genes into tumor cells. Tumor-specific OVV strains can be produced by deleting specific virulence genes from the viral genome. The OVV genome is replicated in the cytoplasm of cells, and thus has no significant risk of genomic integration (41). In the present study, the Beclin1 gene was inserted into the OVV genome in a stable manner and these OVV-Beclin1 particles were used to infect NHL cells. Once expressed in tumor cells, Beclin1 induces autophagy and increases the sensitivity of these cells to chemotherapy-induced cell death (42). Beclin1-mediated autophagy can further lead to the autophagic degradation of proteins and organelles essential for chemotherapy resistance, rendering tumor cells more susceptible to DNA damage and death (Fig. 5).
While a previous study focused on the development of therapeutic approaches capable of inducing apoptotic cell death (43), other modes of cell death also serve as an effective anticancer modality. However, induction of autophagic death is not always successful, underscoring the importance of tailoring cancer treatments to specific targets and disease types (44,45). Previous studies have detected Beclin1 downregulation in human esophageal, breast, cervical, lung and liver cancer (46,47). The upregulation of Beclin1 can induce excessive autophagy in leukemia cells, leading to their death (6). Here, the functional role of Beclin1 in NHL was investigated; Beclin1 was downregulated in this cancer type suggesting that these cells may be sensitive to autophagic induction. These findings are consistent with work by Huang et al (48) demonstrating that

Figure 4. Combination OVV-Beclin1 and R-CHOP inhibits tumor growth in vivo. (A) Establishment of mouse model. A murine non-Hodgkin lymphoma xenograft model was established by implanting BALB/c nude mice with OCI-LY3 cells. Blue arrow, i.t.; red arrow, i.v.; black arrow, S.C. (B) Tumor growth in a murine diffuse large B cell lymphoma xenograft model system was monitored for 30 days. (C) Representative tumor images (n=5). (D) Tumor weight was measured. (E) Murine survival was monitored; mice treated using OVV-Beclin1 exhibited greater survival vs. other treatment groups (P=0.0072). (F) Tumor sections from mice were used for Beclin1 staining; positive cells stained brown. Scale bar, 50 µm. (G) Beclin1-positive cells relative to PBS control animals were counted. Data are presented as the mean ± SD. 'P<0.05 and **P<0.01. OVV, oncolytic Vaccinia virus; R-CHOP, Rituximab, Cyclophosphamide, Epirubicin, Vindesine, Prednisolone; i.t., intratumoral; i.v., intravenous; S.C., subcutaneous.
85% of patients with DLBCL exhibited decreased Beclin1 protein levels following R-CHOP treatment.

The present study developed an OVV-Beclin1 vector which could be used to infect NHL tumor cells and induce excessive autophagy, culminating in cell death. Our previous research showed that OVV-Beclin1 exhibits good therapeutic effects on leukemia and myeloma via dissolving tumor cells and inducing autophagy death (30). Additionally, previous work has shown that Beclin1 upregulation in DLBCL increases PI3KC3 expression and associated phosphorylated-AKT1 activation. Beclin1 interacts with PI3KC3 and then with autophagy-related 12, 5 and 16L and LC3B to facilitate the gradual expansion and maturation of autophagosomes within the cell (49). Autophagy has been found to serve a role in R-CHOP resistance in patients with lymphoma, suggesting that inducing autophagy may be a valuable therapeutic strategy (30).

The present study was able to confirm that OVV-Beclin1 induced autophagic death of NHL cells, indicated by detection of autophagosome formation in these cells. OVV-Beclin1-treated cells did not undergo apoptotic death and dose-dependent increases in virus-induced cytotoxicity were not associated with increases in apoptotic staining or protein levels. At low levels, the induction of autophagy can help tumor cells resist treatment by degrading damaged organelle and proteins. However, excessive autophagy can lead to unrestrained destruction of functional proteins and organelles, compromising cell viability and leading to tumor cell death (50). Here, OVV-Beclin1-induced autophagic death also resulted in the release of viral particles that can then infect proximal tumor cells, leading to further cell death and enhanced R-CHOP efficacy.

Acknowledgements
Not applicable.

Funding
The present study was supported by the Zhejiang Medical Technology Plan Project (grant nos. WKJ-ZJ-1709 and 2020KY052), National Science Foundation of China (grant nos. 81570198 and 81602706) and Zhejiang Provincial Natural Science Foundation of China (grant nos. LY19H160037 and LY17H160062).

Availability of data and materials
All data generated or analyzed in this study are included in this published article.

Authors' contributions
SW, YW, WL and XT designed the study. SX, WF, CY, HP and YW performed the experiments and collected and analyzed data. SX, WF and HP wrote, reviewed and revised the manuscript. All authors read and approved the final version of the manuscript.
Ethics approval and consent to participate

All animal experiments were performed in accordance with ethical standards of the Institutional Animal Use and Care Committee of the Zhejiang Provincial People’s Hospital, and ethical approval (approval no. A20190029) was obtained prior to the commencement of the study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Howlader N, Morton L, Feuer E, Besson C and Engels E: Contributions of subtypes of non-hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev 25: 174-179, 2016.

2. Coccoro N, Anelli L, Zagaria A, Perrone T, Specchia G and Albano F: Molecular complexity of diffuse large b-cell lymphoma: Can it be a roadmap for precision medicine? Cancers 12: 185, 2020.

3. Camcic R, Winkler HC and Hassa PO: Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: A comprehensive review. Mol Cancer 14: 207, 2015.

4. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu Wm, Montes-Moreno S, Dybkaer K, Chiu A, Orzul A, et al.: Autophagy and necroptosis: A model for the impact of autophagy on cell death in T-cell lymphoma. J Exp Med 209: 1989-2003, 2012.

5. Lee D, Lee D, Hwang Y, Seo H, Lee S and Kwon J: The bromodomain inhibitor PFI-3 sensitizes cancer cells to DNA damage as a result of impaired base excision repair. Sci Signal 8: ra83, 2015.

6. Wechman SL, Pradhan AK, DeSalle R, Das SK, Emdad L, Sarkar D, and Schatz JH: Diffuse large B-cell lymphoma: Can genomics predict and guide therapy? Hum Gene Ther 28: 1320-1334, 2017.

7. Aitken AS, Roy DG and Bourgeois-Daigneault MC: Taking a closer look at autophagic cell death in diffuse large B-cell lymphoma. Oncotarget 8: 40533-40543, 2017.

8. Willson C, Pawlovskas E, Bialkowska-Warzecha J, Kaarniranta K and Blasiak J: Autophagy in DNA damage response. Int J Mol Sci 16: 2641-2662, 2014.

9. Zhang D, Tang B, Xie X, Xiao YF, Yang SM and Zhang JW: The interplay between DNA repair and autophagy in cancer therapy. Cancer Biol Ther 16: 1005-1013, 2014.

10. Mizushima N: Autophagy: Process and function. Genes Dev 21: 2861-2873, 2007.

11. Rojas JJ and Thorne SH: Theranostic potential of oncolytic vaccinia virus. Theranostics 2: 363-373, 2012.

12. Qin B, Rogers HJ, Adamson H, Liang J, Wei E, Huang X, et al.: Autophagy is a novel therapeutic target for liver diseases. J Clin Invest 127: 1263-1276, 2017.

13. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, et al.: Autophagy and chemotherapeutic resistance: A promising therapeutic target for cancer treatment. Cell Death Dis 4: e838, 2013.

14. DeCarraro E, Agostinelli C, Embrogio I, Iacobucci I, Casadei B, Bigghenti E, Righi S, Fuligni F, Di Róia AGL, Ferrari A, et al.: Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget 6: 6553-6569, 2015.

15. Czarny P, Pawlovskas E, Bialkowska-Warzecha J, Kaarniranta K and Blasiak J: Autophagy in DNA damage response. Int J Mol Sci 16: 2641-2662, 2014.

16. Hasui K, Wang J, Jia X, Xie X, Xiao YF, Yang SM and Zhang JW: The interplay between DNA repair and autophagy in cancer therapy. Cancer Biol Ther 16: 1005-1013, 2014.

17. Guaman-Ortiz LM, Orellana MIR and Ratovitski EA: Natural compounds as modulators of non-apoptotic cell death in cancer cells. Curr Genom 18: 132-155, 2017.

18. Shen HM and Codogno P: Autophagic cell death: Loch ness monster or endangered species? Autophagy 7: 457-465, 2011.

19. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, et al.: Autophagy and chemotherapeutic resistance: A promising therapeutic target for cancer treatment. Cell Death Dis 4: e838, 2013.

20. DeCarraro E, Agostinelli C, Embrogio I, Iacobucci I, Casadei B, Bigghenti E, Righi S, Fuligni F, Di Róia AGL, Ferrari A, et al.: Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget 6: 6553-6569, 2015.

21. Czarny P, Pawlovskas E, Bialkowska-Warzecha J, Kaarniranta K and Blasiak J: Autophagy in DNA damage response. Int J Mol Sci 16: 2641-2662, 2014.

22. Zhang D, Tang B, Xie X, Xiao YF, Yang SM and Zhang JW: The interplay between DNA repair and autophagy in cancer therapy. Cancer Biol Ther 16: 1005-1013, 2014.

23. Mizushima N: Autophagy: Process and function. Genes Dev 21: 2861-2873, 2007.

24. Rojas JJ and Thorne SH: Theranostic potential of oncolytic vaccinia virus. Theranostics 2: 363-373, 2012.

25. Qin B, Rogers HJ, Adamson H, Liang J, Wei E, Huang X, et al.: Autophagy is a novel therapeutic target for liver diseases. J Clin Invest 127: 1263-1276, 2017.

26. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, et al.: Autophagy and chemotherapeutic resistance: A promising therapeutic target for cancer treatment. Cell Death Dis 4: e838, 2013.

27. DeCarraro E, Agostinelli C, Embrogio I, Iacobucci I, Casadei B, Bigghenti E, Righi S, Fuligni F, Di Róia AGL, Ferrari A, et al.: Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget 6: 6553-6569, 2015.

28. Czarny P, Pawlovskas E, Bialkowska-Warzecha J, Kaarniranta K and Blasiak J: Autophagy in DNA damage response. Int J Mol Sci 16: 2641-2662, 2014.

29. Zhang D, Tang B, Xie X, Xiao YF, Yang SM and Zhang JW: The interplay between DNA repair and autophagy in cancer therapy. Cancer Biol Ther 16: 1005-1013, 2014.

30. Mizushima N: Autophagy: Process and function. Genes Dev 21: 2861-2873, 2007.

31. Rojas JJ and Thorne SH: Theranostic potential of oncolytic vaccinia virus. Theranostics 2: 363-373, 2012.

32. Qin B, Rogers HJ, Adamson H, Liang J, Wei E, Huang X, et al.: Autophagy is a novel therapeutic target for liver diseases. J Clin Invest 127: 1263-1276, 2017.

33. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, et al.: Autophagy and chemotherapeutic resistance: A promising therapeutic target for cancer treatment. Cell Death Dis 4: e838, 2013.

34. DeCarraro E, Agostinelli C, Embrogio I, Iacobucci I, Casadei B, Bigghenti E, Righi S, Fuligni F, Di Róia AGL, Ferrari A, et al.: Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget 6: 6553-6569, 2015.

35. Czarny P, Pawlovskas E, Bialkowska-Warzecha J, Kaarniranta K and Blasiak J: Autophagy in DNA damage response. Int J Mol Sci 16: 2641-2662, 2014.

36. Zhang D, Tang B, Xie X, Xiao YF, Yang SM and Zhang JW: The interplay between DNA repair and autophagy in cancer therapy. Cancer Biol Ther 16: 1005-1013, 2014.

37. Mizushima N: Autophagy: Process and function. Genes Dev 21: 2861-2873, 2007.
40. Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z and Bartlett DL: Vaccinia virus-mediated cancer immunotherapy: Cancer vaccines and oncolytics. J Immunother Cancer 7: 6, 2019.

41. Liu Z, Ge Y, Wang H, Ma C, Feist M, Ju S, Guo ZS and Bartlett DL: Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9: 4682, 2018.

42. Hill SM, Wrobel L and Rubinsztein DC: Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation. Cell Death Differ 26: 617-629, 2019.

43. Place DE and Kanneganti TD: Cell death-mediated cytokine release and its therapeutic implications. J Exp Med 216: 1474-1486, 2019.

44. Torii S, Honda S, Murohashi M, Yamaguchi H and Shimizu S: Autophagy involvement in oncogenesis. Cancer Sci 111: 3993-3999, 2020.

45. Levy JM and Thorburn A: Autophagy in cancer: Moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ 27: 843-857, 2020.

46. Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, Buchan JR and Cho WC: Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci 18: 367, 2017.

47. Zhang J, Yang S, Wang K, Huang Y, Yang N, Yang Z, Zheng Z and Wang Y: Crocin induces autophagic cell death and inhibits cell invasion of cervical cancer SiHa cells through activation of PI3K/AKT. Ann Transl Med 8: 1180, 2020.

48. Huang JJ, Zhu YJ, Lin TY, Jiang WQ, Huang HQ and Li ZM: Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Hum Pathol 42: 1459-1466, 2011.

49. Wang Z, Zhu S, Zhang G and Liu S: Inhibition of autophagy enhances the anticancer activity of bortezomib in B-cell acute lymphoblastic leukemia cells. Am J Cancer Res 5: 639-650, 2015.

50. Zhu Y, Jia H, Gao G, Pan GY, Jiang YW, Li P, Zhou N, Li C, She C, Ulrich NW, et al.: Mitochondria-acting nanomicelles for destruction of cancer cells via excessive mitophagy/autophagy-driven lethal energy depletion and phototherapy. Biomaterials 232: 119668, 2020.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.